Pediatric Factor XIII Deficiency Treatment & Management

  • Author: Helge Hartung, MD; Chief Editor: Max J Coppes, MD, PhD, MBA   more...
 
Updated: Mar 9, 2011
 

Medical Care

Medical care includes the following:

  • Plasma, cryoprecipitate, and factor XIII (FXIII) concentrates have been used for replacement of factor XIII and the treatment of bleeding. The treatment of choice is plasma-derived factor XIII concentrate that is pasteurized to provide virologic safety and is less likely than plasma to cause systemic reactions. Recombinant factor XIII-A2 concentrates are currently being evaluated in clinical trials.
  • Because levels of factor XIII above 3-5% are usually sufficient to prevent spontaneous bleeding and because the plasma half-life is long (7-12 d), prophylaxis is the management strategy of choice. Prophylactic therapy with factor XIII concentrate 10-20 U/kg every 4-6 weeks provides adequate plasma levels in most patients. The dose and frequency should be tailored to plasma levels and clinical efficacy for each patient.
  • The half-life of factor XIII is shorter during pregnancy; therefore, treating pregnant patients requires more frequent dosing. In addition, a booster dose is recommended during labor to decrease the risk of bleeding in the mother.
  • Neonates at risk for factor XIII deficiency because of their family history should be screened at birth and treated promptly if factor XIII deficiency is found.
Next

Surgical Care

In preparation for surgical procedures, patients should receive factor XIII concentrate immediately before surgery to ensure optimal hemostasis and wound healing.

Previous
Next

Consultations

Consult a hematologist and/or hemostasis specialist for patients who require factor XIII replacement therapy.

Genetic counseling and family studies should be part of a complete evaluation.

Previous
Proceed to Medication
 
 
Contributor Information and Disclosures
Author

Helge Hartung, MD  Attending Physician, Division of Hematology, Center for Cancer and Blood Disorders

Disclosure: Nothing to disclose.

Specialty Editor Board

Gary R Jones, MD  Associate Medical Director, Clinical Development, Berlex Laboratories

Gary R Jones, MD is a member of the following medical societies: American Academy of Pediatrics, American Society of Pediatric Hematology/Oncology, and Western Society for Pediatric Research

Disclosure: Nothing to disclose.

Mary L Windle, PharmD  Adjunct Associate Professor, University of Nebraska Medical Center College of Pharmacy; Pharmacy Editor, eMedicine

Disclosure: Nothing to disclose.

James L Harper, MD  Associate Professor, Department of Pediatrics, Division of Hematology/Oncology and Bone Marrow Transplantation, Associate Chairman for Education, Department of Pediatrics, University of Nebraska Medical Center; Assistant Clinical Professor, Department of Pediatrics, Creighton University; Director, Continuing Medical Education, Children's Memorial Hospital; Pediatric Director, Nebraska Regional Hemophilia Treatment Center

James L Harper, MD is a member of the following medical societies: American Academy of Pediatrics, American Association for Cancer Research, American Federation for Clinical Research, American Society of Hematology, American Society of Pediatric Hematology/Oncology, Council on Medical Student Education in Pediatrics, and Hemophilia and Thrombosis Research Society

Disclosure: Nothing to disclose.

Helen SL Chan, MBBS, FRCP(C), FAAP  Senior Scientist, Research Institute; Professor, Division of Hematology/Oncology, Department of Pediatrics, The Hospital for Sick Children, University of Toronto, Canada

Helen SL Chan, MBBS, FRCP(C), FAAP is a member of the following medical societies: American Academy of Pediatrics, American Association for Cancer Research, American Society of Hematology, and Royal College of Physicians and Surgeons of Canada

Disclosure: Nothing to disclose.

Chief Editor

Max J Coppes, MD, PhD, MBA  Senior Vice President, Center for Cancer and Blood Disorders, Children's National Medical Center; Professor of Medicine, Oncology, and Pediatrics, Georgetown University School of Medicine; Clinical Professor of Pediatrics, George Washington University School of Medicine and Health Sciences

Max J Coppes, MD, PhD, MBA is a member of the following medical societies: American Association for Cancer Research, American Society of Pediatric Hematology/Oncology, and Society for Pediatric Research

Disclosure: Nothing to disclose.

References

  1. Karimi M, Bereczky Z, Cohan N, Muszbek L. Factor XIII Deficiency. Semin Thromb Hemost. Jun 2009;35(4):426-38. [Medline].

  2. Anwar R, Minford A, Gallivan L, Trinh CH, Markham AF. Delayed umbilical bleeding--a presenting feature for factor XIII deficiency: clinical features, genetics, and management. Pediatrics. Feb 2002;109(2):E32. [Medline].

  3. Todd T, J Perry D. A review of long-term prophylaxis in the rare inherited coagulation factor deficiencies. Haemophilia. Nov 11 2009;[Medline].

  4. Anwar R, Miloszewski KJ. Factor XIII deficiency. Br J Haematol. Dec 1999;107(3):468-84. [Medline].

  5. Ariens RA, Lai TS, Weisel JW, Greenberg CS, Grant PJ. Role of factor XIII in fibrin clot formation and effects of genetic polymorphisms. Blood. Aug 1 2002;100(3):743-54. [Medline].

  6. Ichinose A. Physiopathology and regulation of factor XIII. Thromb Haemost. Jul 2001;86(1):57-65. [Medline].

  7. Ichinose A, Asahina T, Kobayashi T. Congenital blood coagulation factor XIII deficiency and perinatal management. Curr Drug Targ. 2005;6:541-549.

  8. Israels LG, Israels ED. Fibrinogen, factor XIII, and fibrinolysis. In: Mechanisms in Hematology. 3rd ed. Concord ON: Core Health Services, Inc; 2002:355-367.

  9. Jennings I, Kitchen S, Woods TA, Preston FE,. Problems relating to the laboratory diagnosis of factor XIII deficiency: a UK NEQAS study. J Thromb Haemost. Dec 2003;1(12):2603-8. [Medline].

  10. Lovejoy AE, Reynolds TC, Visich JE, Butine MD, Young G, Belvedere MA, et al. Safety and pharmacokinetics of recombinant factor XIII-A2 administration in patients with congenital factor XIII deficiency. Blood. Jul 1 2006;108(1):57-62. [Medline].

  11. Nugent DJ. Prophylaxis in rare coagulation disorders -- factor XIII deficiency. Thromb Res. 2006;118 Suppl 1:S23-8. [Medline].

 
Previous
Next
 
Activation of factor XIII (FXIII) by thrombin and calcium is a 2-step process. Thrombin cleaves an arginine-lysine bond in the A subunit and calcium causes dissociation of the B subunit, exposing the active site on the A subunit (XIIIa).
 
 
 
All material on this website is protected by copyright, Copyright © 1994-2012 by WebMD LLC.
This website also contains material copyrighted by 3rd parties.

DISCLAIMER: The content of this Website is not influenced by sponsors. The site is designed primarily for use by qualified physicians and other medical professionals. The information contained herein should NOT be used as a substitute for the advice of an appropriately qualified and licensed physician or other health care provider. The information provided here is for educational and informational purposes only. In no way should it be considered as offering medical advice. Please check with a physician if you suspect you are ill.